• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Prostatype Genomics

0.22 SEK

-40.59 %

Less than 1K followers

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-40.59 %
+7.57 %
-31.98 %
+51.27 %
+93.62 %
-41.33 %
-99.23 %
-99.92 %
-99.84 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Read more
Market cap
117.73M SEK
Turnover
695.53K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
23.7.
2026

Interim report Q2'26

11.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release29.06.2026 klo 21.00

The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release22.06.2026 klo 19.45

Bulletin from annual general meeting in Prostatype Genomics AB (publ)

Prostatype Genomics
Regulatory press release01.06.2026 klo 11.45

Prostatype Genomics publishes Annual Report for 2025

Prostatype Genomics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release25.05.2026 klo 09.45

Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype® in the United States

Prostatype Genomics
Regulatory press release19.05.2026 klo 23.00

NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)

Prostatype Genomics
Regulatory press release19.05.2026 klo 22.50

Prostatype Genomics AB announces the Board of Directors’ intention to resolve on a rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release26.02.2026 klo 17.45

Prostatype Genomics publishes year-end report for 2025

Prostatype Genomics
Regulatory press release12.01.2026 klo 09.55

Loan financing of SEK 10 million to Prostatype Genomics AB

Prostatype Genomics
Regulatory press release08.01.2026 klo 20.30

Prostatype Genomics U.S. Validation study by Veterans Affairs (VA) is published

Prostatype Genomics
Regulatory press release25.11.2025 klo 15.30

Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results

Prostatype Genomics
Press release19.11.2025 klo 09.06

BioStock: Video from Prostatype Genomic's presentation at BioStock Life Science Summit 2025

Prostatype Genomics
Regulatory press release11.11.2025 klo 16.45

Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics

Prostatype Genomics
Regulatory press release24.09.2025 klo 23.45

New shares from exercise of warrants of series TO5 registered

Prostatype Genomics
Regulatory press release18.09.2025 klo 20.00

Prostatype Genomics AB receives SEK 11.5 million in connection with warrants of series TO5

Prostatype Genomics
Regulatory press release12.09.2025 klo 10.05

The last day of trading in Prostatype Genomics AB’s warrants of series TO5 is on Monday

Prostatype Genomics
Regulatory press release03.09.2025 klo 21.55

Prostatype Genomics AB enters into pre-subscription and top-down underwriting commitments corresponding to 37.2 percent in ongoing warrant exercise

Prostatype Genomics
Regulatory press release03.09.2025 klo 09.45

The exercise period for Prostatype Genomics AB’s warrants of series TO5 commences today

Prostatype Genomics
Regulatory press release02.09.2025 klo 09.45

Prostatype Genomics AB announces fixed exercise price for warrants of series TO5

Prostatype Genomics
Press release28.08.2025 klo 17.00

Update regarding Prostatype Genomics’ application to Medicare concerning reimbursement for Prostatype® in USA

Prostatype Genomics
Regulatory press release26.08.2025 klo 09.30

Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype® to insurance companies in the USA

Prostatype Genomics